With great attention paid to immune checkpoint molecules such as PD-1 and its ligand PDL1 in tumor immunology [216], several studies were conducted to test whether a blockade of immunosuppressive TME could rescue anti-tumor activity in HNSCC patients. This evidence concerns the gene CD274 and neoplasm.